课题基金 / 基金详情

Identification of a low molecular weight peptide of CD109 as an anti-scarring agent

Identification of a low molecular weight peptide of CD109 as an anti-scarring agent
CD109 低分子量肽作为抗疤痕剂的鉴定
批准号：
196281
负责人：
Philip Anie
金额：
$10.93万
依托单位：
Montreal General Hospital
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2009
资助国家：
加拿大
项目状态：
已结题
起止时间：
2009-10-01 至 2010-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=196281&lang=en
关键词：
Cd109 Scarring Tgf-Beta Wound Healing

项目摘要

项目成果

Philip Anie的其他基金

相似基金

相关文献

中文摘要
翻译
伤口愈合是对组织损伤的正常反应，涉及许多生长因子，这些生长因子控制细胞生长、运动（迁移）和细胞外基质（ECM）的产生，细胞外基质为修复组织提供结构支持。改变gro
英文摘要
Wound healing is a normal response to tissue injury and involves many growth factors that control cell growth, movement (migration) and production of the extracellular matrix (ECM) that provides structural support to the repairing tissue. Transforming gro
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma
Role of CD109 in regulating cellular signaling and responses in skin and oral squamous cell carcinoma cells
Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways
Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways
海外基金